Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTER-M3 trial of nivolumab plus radiotherapy for metastatic mucosal melanoma
jRCT1051200028Phase 2Completed
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in mucosal melanoma (MM) and melanoma. Primary endpoint: Response rate. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
mucosal melanoma (MM)melanoma
Beyond the preview
Go deeper on jRCT1051200028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051200028.